Journal of Antimicrobial Chemotherapy (1999) 44, 611-619
© 1999 The British Society for Antimicrobial Chemotherapy
New species-related MIC breakpoints for early detection of development of resistance among Gram-negative bacteria in Swedish intensive care units
a Division of Infectious Diseases b Clinical Microbiology; University Hospital, S-581 85 Linköping, Sweden; Divisions of Clinical Microbiology c S-541 85 Skövde; d S-141 86 Hudding e Östra S-416 85 Gothenburg; f Karolinska S-171 76 Stockholm; g S-551 85 Jönköping, Sweden
The frequency of decreased antibiotic susceptibility among 534 Gram-negative aerobic bacilli from patients admitted to intensive care units at eight hospitals in Sweden during 1997 was evaluated. MICs of cefepime, ceftazidime, ceftriaxone, ciprofloxacin, gentamicin, imipenem and piperacillin–tazobactam were determined using Etest. Reduced susceptibility (resistant and intermediate/indeterminate susceptible strains) was defined according to the MIC breakpoints of the British Society for Antimicrobial Chemotherapy (BSAC), the National Committee for Clinical Laboratory Standards (NCCLS) and the new species-related breakpoints of the Swedish Reference Group for Antibiotics (SRGA). The BSAC/NCCLS/SRGA breakpoints for susceptible category (mg/L) of Enterobacteriaceae are: cefepime, not available (NA)/8/0.5; ceftazidime, 2/8/2; ceftriaxone, NA/8/0.5; ciprofloxacin, 1/1/0.12; gentamicin, 1/4/2; imipenem, 4/4/1; and piperacillin–tazobactam, NA/16/16. The most frequently isolated organisms were Escherichia coli (n = 160; 30%), Klebsiella spp. (n = 84; 16%), Enterobacter spp. (n = 77; 14%), Pseudomonas aeruginosa (n = 64; 12%) andProteus spp. (n = 28; 5%). Decreased susceptibility among E. coliusing the BSAC/NCCLS/SRGA respective breakpoints (%) were: cefepime, NA/0/2; ceftazidime, 2/2/2; ceftriaxone, NA/1/2; ciprofloxacin, 2/2/8; gentamicin, 21/0/3; imipenem, 0/0/2; and piperacillin-tazobactam, NA/4/4. Corresponding levels of decreased susceptibility (%) among Klebsiellaspp. were: cefepime, NA/0/5; ceftazidime, 2/1/2; ceftriaxone, NA/1/10; ciprofloxacin, 4/4/19; gentamicin, 25/2/5; imipenem, 0/0/0; and piperacillin-tazobactam, NA/10/10; and among Enterobacter spp. were: cefepime, NA/1/19; ceftazidime, 30/29/30; ceftriaxone, NA/30/36; ciprofloxacin, 3/3/15; gentamicin,18/0/0; imipenem, 0/0/5; and piperacilllin-tazobactam, NA/27/27. In conclusion, the species-related SRGA breakpoints detected Gram-negative isolates with decreased susceptibility in comparison with the native population with higher frequency than did the NCCLS breakpoints. The BSAC breakpoints for susceptible organisms were similar to NCCLS for ciprofloxacin and imipenem, and similar to SRGA for ceftazidime but lower than both NCCLS and SRGA for gentamicin, causing a much higher frequency of decreased susceptibility to gentamicin.
* Corresponding author. Fax: +46-13-159-441; E-mail: hakan.hanberger{at}inf.liu.se
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Fuursted and H. Schumacher Significance of low-level resistance to ciprofloxacin in Klebsiella pneumoniae and the effect of increased dosage of ciprofloxacin in vivo using the rat granuloma pouch model J. Antimicrob. Chemother., September 1, 2002; 50(3): 421 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hallgren, H. Abednazari, C. Ekdahl, H. Hanberger, M. Nilsson, A. Samuelsson, E. Svensson, L. E. Nilsson, and t. Swedish ICU Study Group Antimicrobial susceptibility patterns of enterococci in intensive care units in Sweden evaluated by different MIC breakpoint systems J. Antimicrob. Chemother., July 1, 2001; 48(1): 53 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Preston, M. R. Turnak, M. R. Jacobs, P. C. Appelbaum, G. G. Zhanel, D. E. Low, and W. Craig Assumed versus Approved Breakpoints Antimicrob. Agents Chemother., November 1, 2000; 44(11): 3243 - 3245. [Full Text]
|
|
|
|
|
|
T. Gottlieb and C. Wolfson Comparison of the MICs of cefepime for extended-spectrum {beta}-lactamase-producing and non-extended-spectrum {beta}-lactamase-producing strains of Enterobacter cloacae J. Antimicrob. Chemother., August 1, 2000; 46(2): 330 - 332. [Full Text] [PDF]
|
|